May 2019

SeeO2 Energy receives Mitacs Environmental Award

Groundbreaking technology converts waste carbon dioxide into high-value fuels and chemicals

READ MORE

Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim Therapeutics for the Treatment of Autoimmune Diseases

Parvus eligible to receive upfront and milestone payments exceeding $800 Million plus royalties on net sales

READ MORE

University of Calgary discovery of potential treatment for autoimmune diseases takes step forward

Parvus Therapeutics announces worldwide collaboration and license agreement with Genentech to develop and commercialize Navacim therapeutics

READ MORE

Secret sauce: UCalgary researchers turn greenhouse gases into carbon fibre

READ MORE

Direct-C receives Sustainable Development Technology Canada grant

READ MORE